The dysregulation of CD226 signaling—through genetic polymorphisms, altered expression, or imbalanced ligand interactions—disrupts immune homeostasis and is mechanistically linked to aberrant inflammation, autoimmunity, and impaired pathogen/tumor surveillance. This evidence concerns the gene CD226 and neoplasm.